PA8531601A1 - Nuevos heteroaromatos - Google Patents

Nuevos heteroaromatos

Info

Publication number
PA8531601A1
PA8531601A1 PA20018531601A PA8531601A PA8531601A1 PA 8531601 A1 PA8531601 A1 PA 8531601A1 PA 20018531601 A PA20018531601 A PA 20018531601A PA 8531601 A PA8531601 A PA 8531601A PA 8531601 A1 PA8531601 A1 PA 8531601A1
Authority
PA
Panama
Prior art keywords
heteroaromatos
new
prevention
treatment
pharmaceutically acceptable
Prior art date
Application number
PA20018531601A
Other languages
English (en)
Inventor
Johannes Aebi
Jean Ackermann
Henrietta Dehmlow
Hans-Peter Maerki
Olivier Morand
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8531601A1 publication Critical patent/PA8531601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LOS COMPUESTOS DE FORMULA (I) EN DONDE U,A1,A2,A3,A4,V,X,Y,Z,Q,M Y N SON COMO SE DEFINE EN LA DESCRIPCION Y REIVINDICACIONES Y LAS SALES FARMACEUTICAMENTE ACEPTABLES Y/O ESTERES FARMACEUTICAMENTE ACEPTABLES DE LAS MISMAS. LOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE ENFERMEDADES QUE ESTAN ASOCIADAS CON LA 2,3-OXIDOESCULENO-LANOSTERL CICLASA COMO SON HIPERCOLESTEROLEMIA, HIPERLIPIDEMIA, ARTERIOSCLEROSIS, ENFERMEDADES VASCULARES, MICOSI, CALCULOS BILIARES, TUMORES Y/O DESORDENES HIPERPROLIFERATIVOS, Y EL TRATAMIENTO Y(O PREVENCION DE LA DISMINUCION A LA TOLERANCIA DE LA GLUCOSA Y DIABETES.
PA20018531601A 2000-11-02 2001-11-01 Nuevos heteroaromatos PA8531601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00123826 2000-11-02

Publications (1)

Publication Number Publication Date
PA8531601A1 true PA8531601A1 (es) 2003-02-14

Family

ID=8170270

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018531601A PA8531601A1 (es) 2000-11-02 2001-11-01 Nuevos heteroaromatos

Country Status (21)

Country Link
US (3) US6951879B2 (es)
EP (1) EP1334094B1 (es)
JP (1) JP4012064B2 (es)
KR (1) KR100545430B1 (es)
CN (1) CN1261429C (es)
AR (1) AR034271A1 (es)
AT (1) ATE286042T1 (es)
AU (2) AU2002214029B2 (es)
BR (1) BR0115075A (es)
CA (1) CA2426009C (es)
DE (1) DE60108164T2 (es)
DK (1) DK1334094T3 (es)
ES (1) ES2233703T3 (es)
GT (1) GT200100220A (es)
MX (1) MXPA03003845A (es)
PA (1) PA8531601A1 (es)
PE (1) PE20020600A1 (es)
PT (1) PT1334094E (es)
UY (1) UY27009A1 (es)
WO (1) WO2002036584A1 (es)
ZA (1) ZA200302742B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60135230D1 (de) 2000-08-16 2008-09-18 Hoffmann La Roche Aminocyclohexan-derivate
US7012077B2 (en) * 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
JP4912314B2 (ja) * 2004-10-26 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 因子Ｘａ化合物
EP1902023A4 (en) * 2005-06-30 2009-08-12 Bayer Cropscience Ag IMPROVED PROCESS FOR PREPARING PHENYLALKYL SUBSTITUTED INSECTICIDE HETEROCYCLES (DISUBSTITUTED PROPENYL)
FR2913019A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Composes heterocycliques comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
WO2009069011A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
AU2008331167A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
CA2822207A1 (en) * 2010-12-27 2012-07-05 The Curators Of The University Of Missouri Oxidosqualene cyclase as a protein target for anticancer therapeutics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598839A (en) * 1969-06-30 1971-08-10 Parke Davis & Co Phenylbenzothiophene compounds
GR75101B (es) * 1980-10-23 1984-07-13 Pfizer
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
DE3905364A1 (de) 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
EP0530149A1 (de) * 1991-08-30 1993-03-03 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
CA2190699A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
CA2190708A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні

Also Published As

Publication number Publication date
BR0115075A (pt) 2003-07-29
DE60108164T2 (de) 2006-03-02
DE60108164D1 (de) 2005-02-03
AU2002214029B2 (en) 2004-12-23
ZA200302742B (en) 2004-07-08
US6951879B2 (en) 2005-10-04
CN1261429C (zh) 2006-06-28
PE20020600A1 (es) 2002-07-08
KR100545430B1 (ko) 2006-01-24
US20070099985A1 (en) 2007-05-03
CA2426009A1 (en) 2002-05-10
EP1334094B1 (en) 2004-12-29
ATE286042T1 (de) 2005-01-15
ES2233703T3 (es) 2005-06-16
AR034271A1 (es) 2004-02-18
US7449483B2 (en) 2008-11-11
US20020086891A1 (en) 2002-07-04
UY27009A1 (es) 2002-06-20
WO2002036584A1 (en) 2002-05-10
US7173043B2 (en) 2007-02-06
MXPA03003845A (es) 2003-07-28
US20050267200A1 (en) 2005-12-01
EP1334094A1 (en) 2003-08-13
DK1334094T3 (da) 2005-05-02
KR20030045166A (ko) 2003-06-09
GT200100220A (es) 2002-07-04
JP4012064B2 (ja) 2007-11-21
CA2426009C (en) 2008-10-07
AU1402902A (en) 2002-05-15
CN1471522A (zh) 2004-01-28
JP2004513124A (ja) 2004-04-30
PT1334094E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
PA8557001A1 (es) Nuevos derivados de pirrolidina
UY26782A1 (es) Derivados del benzotiazol
PA8566101A1 (es) Nuevos derivados de piridina y pirimidina
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
ECSP056240A (es) Derivados de pirido[2,1-a]isoquinolina como inhibidores de dpp-iv
PA8562801A1 (es) Nuevos derivados de pirido (2,1-a) isoquinolina
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
UY27300A1 (es) Nuevos derivados de quinolina
AR027355A1 (es) Acidos tiazolidincarboxilicos
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
PA8566201A1 (es) Nuevos derivados de piridina y quinolina
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
PA8525101A1 (es) Nuevos derivados de aminociclohexanol
PA8531601A1 (es) Nuevos heteroaromatos
PT1150704E (pt) Melagatran para o tratamento da inflamacao
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
IT1318667B1 (it) Medicamento antinfiammatorio.
PA8584501A1 (es) Nuevos derivados de oxazol
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
BR0116263A (pt) Derivados de diidroindol e tetraidroquinolina